Corticosteroids and adrenoceptor agonists: The compliments for combination therapy in chronic airways diseases

European Journal of Pharmacology

Volumn 533, Issue 1-3, 2006, Pages 28-35

  Sin, Don D ^a   Man, S F Paul ^b  

^a ST PAUL S HOSPITAL   (Canada)

^b NONE

Author keywords

Adrenergic beta agonist; Asthma; COPD; Glucocorticoid

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; HISTAMINE; MONTELUKAST; SALMETEROL;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; HUMAN; LUNG FUNCTION; MORTALITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANDROSTADIENES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, GLUCOCORTICOID;

EID: 33644763964     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.12.049     Document Type: Review

References (46)

1. I.M. Adcock, and K. Ito Molecular mechanisms of corticosteroid actions Monaldi Arch. Chest Dis. 55 2000 256 266
2. 2-adrenergic receptor function in human nasal mucosa Am. J. Respir. Crit. Care Med. 155 1997 704 710
3. P.J. Barnes Molecular mechanisms of steroid action in asthma J. Allergy Clin. Immunol. 1 1997 159 168
4. P.J. Barnes Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids Eur. Respir. J. 19 2002 182 191
5. P.J. Barnes, S.D. Shapiro, and R.A. Pauwels Chronic obstructive pulmonary disease: molecular and cellular mechanisms Eur. Respir. J. 22 2003 672 688
6. P.J. Barnes, K. Ito, and I.M. Adcock Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase Lancet 363 2004 731 733
7. A.C. Boyter, and D.T. Steinke Changes in prescribing of inhaled corticosteroids (1999-2002) in Scotland Pharmacoepidemiol. Drug Saf. 14 2005 203 209
8. P. Burney, S. Suissa, J.B. Soriano, W.M. Vollmer, G. Viegi, S.D. Sullivan, L.M. Fabbri, D.D. Sin, P. Ernst, D. Coultas, J. Bourbeau, D.W. Mapel, K. Weiss, T. McLaughlin, D. Price, M.C. Sturkenboom, R. Taylor, and G.W. Hagan The pharmacoepidemiology of COPD: recent advances and methodological discussion Eur. Respir. J. Suppl. 43 2003 1s 44s
9. W.W. Busse, and R.F. Lemanske Jr. Asthma N. Engl. J. Med. 344 2001 350 362
10. P.M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, and H. Olsson Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Eur. Respir. J. 22 2003 912 919
11. P. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. Pride, A. Gulsvik, J. Anderson, C. Maden TRial of Inhaled STeroids ANd long-acting beta2 agonists study group Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet 361 2003 449 456
12. G.W. Chalmers, K.J. Macleod, S.A. Little, L.J. Thomson, C.P. McSharry, and N.C. Thomson Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma Thorax 57 2002 226 230
13. O. Eickelberg, M. Roth, R. Lorx, V. Bruce, J. Rudiger, M. Johnson, and L.H. Block Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells J. Biol. Chem. 274 1999 1005 1010
14. P.A. Finney, L.E. Donnelly, M.G. Belvisi, T.T. Chuang, M. Birrell, A. Harris, J.C. Mak, C. Scorer, P.J. Barnes, I.M. Adcock, and M.A. Giembycz Chronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha) Br. J. Pharmacol. 132 2001 1261 1270
15. Global Initiative for Asthma (GINA). Workshop Report, Global Strategy for Asthma Management and Prevention. Available at http://www.ginasthma.com (accessed July 1, 2005).
16. Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD Workshop Report (updated 2003). Available at http://www.goldcopd.com (accessed July 1, 2005).
17. J.C. Hogg Pathophysiology of airflow limitation in chronic obstructive pulmonary disease Lancet 364 2004 709 721
18. P.K. Jeffery Differences and similarities between chronic obstructive pulmonary disease and asthma Clin. Exp. Allergy 29 Suppl. 2 1999 14 26
19. 2-adrenoceptor Am. J. Respir. Crit. Care Med. 158 1998 146 153
20. 2- adrenoceptor agonists W.W. Busse S.T. Holgate Asthma and Rhinitis 1995 Blackwell Scientific Publications Boston, MA 1278 1295
21. S.H. Korn, A. Jerre, and R. Brattsand Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells Eur. Respir. J. 17 2001 1070 1077
22. 2-adrenoceptor in vivo J. Clin. Invest. 96 1995 99 106
23. A. Nieves, A. Magnan, S. Boniface, H. Proudhon, A. Lanteaume, S. Romanet, D. Vervloet, and P. Godard Phenotypes of asthma revisited upon the presence of atopy Respir. Med. 99 2005 347 354
24. P.M. O'Byrne, P.J. Barnes, R. Rodriguez-Roisin, E. Runnerstrom, T. Sandstrom, K. Svensson, and A. Tattersfield Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial Am. J. Respir. Crit. Care Med. 164 2001 1392 1397
25. P.M. O'Byrne, H. Bisgaard, P.P. Godard, M. Pistolesi, M. Palmqvist, Y. Zhu, T. Ekstrom, and E.D. Bateman Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma Am. J. Respir. Crit. Care Med. 171 2005 129 136
26. R.D. O'Connor, R. Stanford, C. Crim, S.W. Yancey, L. Edwards, K.A. Rickard, and P. Dorinsky Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Ann. Allergy, Asthma, & Immun. 93 2004 581 588
27. R.A. Pauwels, and K.F. Rabe Burden and clinical features of chronic obstructive pulmonary disease (COPD) Lancet 364 2004 613 620
28. R.A. Pauwels, C.G. Lofdahl, D.S. Postma, A.E. Tattersfield, P. O'Byrne, P.J. Barnes, A. Ullman Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group Effect of inhaled formoterol and budesonide on exacerbations of asthma N. Engl. J. Med. 337 1997 1405 1411
29. W.R. Pieters, K.K. Wilson, H.C. Smith, J.J. Tamminga, and S. Sondhi Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma Treat. Respir. Med. 4 2005 129 138
30. Y. Qiu, D. Parker, N.C. Barnes, M. Johnson, I. Pavord, and P. Jeffrey The effect of salmeterol/fluticasone propionate on eosinophils and mast cells in COPD Proceedings of the American Thoracic Society vol. 2 2005 A132
31. M. Roth, P.R. Johnson, J.J. Rudiger, G.G. King, Q. Ge, J.K. Burgess, G. Anderson, M. Tamm, and J.L. Black Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling Lancet 360 2002 1293 1299
32. M. Roth, P.R. Johnson, P. Borger, M.P. Bihl, J.J. Rudiger, G.G. King, Q. Ge, K. Hostettler, J.K. Burgess, J.L. Black, and M. Tamm Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells N. Engl. J. Med. 351 2004 560 574
33. D.D. Sin, and S.F. Man Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma Arch. Intern. Med. 162 2002 1591 1595
34. D.D. Sin, F.A. McAlister, S.F. Man, and N.R. Anthonisen Contemporary management of chronic obstructive pulmonary disease: scientific review JAMA 290 2003 2301 2312
35. D.D. Sin, J. Man, H. Sharpe, W.Q. Gan, and S.F. Man Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis JAMA 292 2004 367 376
36. J.B. Soriano, J. Vestbo, N.B. Pride, V. Kiri, C. Maden, and W.C. Maier Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice Eur. Respir. J. 20 2002 819 825
37. F.M. Spoelstra, D.S. Postma, H. Hovenga, J.A. Noordhoek, and H.F. Kauffman Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts Thorax 57 2002 237 241
38. S. Suissa Inhaled steroids and mortality in COPD: bias from unaccounted immortal time Eur. Respir. J. 23 2004 391 395
39. S. Suissa, P. Ernst, S. Benayoun, M. Baltzan, and B. Cai Low-dose inhaled corticosteroids and the prevention of death from asthma N. Engl. J. Med. 343 2000 332 336
40. S. Suissa, P. Ernst, and A. Kezouh Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma Thorax 57 2002 880 884
41. W. Szafranski, A. Cukier, A. Ramirez, G. Menga, R. Sansores, S. Nahabedian, S. Peterson, and H. Olsson Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur. Respir. J. 21 2003 74 81
42. K.S. Tan, A. Grove, A. McLean, Y. Gnosspelius, I.P. Hall, and B.J. Lipworth Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients Am. J. Respir. Crit. Care Med. 156 1997 28 35
43. J.E. Tomlinson, A.D. McMahon, R. Chaudhuri, J.M. Thompson, S.F. Wood, and N.C. Thomson Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma Thorax 60 2005 282 287
44. O.S. Usmani, K. Ito, K. Maneechotesuwan, M. Ito, M. Johnson, P.J. Barnes, and I.M. Adcock Glucocorticoid receptor nuclear translocation in airway cells following inhaled combination therapy Am. J. Respir. Crit. Care Med. 2005 (Available at http://ajrccm.atsjournals.org.login.ezproxy.library.ualberta.ca/ cgi/reprint/200408-1041OCv1 )
45. J. Vestbo TORCH Study Group The TORCH (towards a revolution in COPD health) survival study protocol Eur. Respir. J. 24 2004 206 210
46. J. Zhu, Y. Qiu, N.C. Barnes, M. Johnson, I. Pavord, and P.K. Jeffery The effect of salmeterol/fluticasone propionate on pro-inflammatory gene expression in COPD Proceedings of the American Thoracic Society vol. 2 2005 A127